Waldencast—parent company of renowned brands Milk Makeup and Obagi Medical—has announced its acquisition of Novaestiq Corp., a leading name in the medical aesthetics sector. This acquisition underscores Waldencast’s commitment to enhancing its offerings and solidifying its position in the rapidly growing field of aesthetic medicine.

As part of this strategic acquisition, Waldencast has also secured the U.S. rights to Novaestiq’s acclaimed injectable hyaluronic acid line, Saypha®. This product line is well-regarded for its innovative formulations and effectiveness in aesthetic applications, making it a valuable addition to Waldencast’s portfolio. Currently, Saypha® is seeking approval from the U.S. Food and Drug Administration (FDA), marking a crucial step toward providing advanced aesthetic solutions to the U.S. market.

In recent years, the demand for non-surgical aesthetic procedures has surged, highlighting the need for safe, effective products that align with evolving consumer preferences. With the integration of Saypha® under the Obagi Medical brand, Waldencast is positioning itself to meet these demands head-on. The acquisition not only enhances Waldencast’s product lineup but also reflects a broader trend in the industry where established brands are actively seeking to diversify their offerings through strategic partnerships and acquisitions.